Cancer investigation
-
Cancer investigation · Jun 2013
Multicenter StudySorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC). ⋯ Fifty percent doses of sorafenib and everolimus were required when these drugs were combined. No increase in efficacy was suggested; toxicity was modestly increased.